LeMaitre Vascular, Inc. (NASDAQ: LMAT) has experienced a modest stock decline of 0.7 USD (-0.80%) in the latest trading session, closing at 86.79 USD. This update matters to investors and stakeholders as the company remains a reliable player in the medical devices sector despite short-term fluctuations.
Company Overview
LeMaitre Vascular, Inc., headquartered in Burlington, Massachusetts, designs and markets medical devices and implants for the treatment of peripheral vascular disease. The product portfolio includes angioscopes, embolectomy and occlusion catheters, perfusion and thrombectomy catheters, carotid shunts, radiopaque tape, valvulotomes, vascular grafts, and vascular and cardiac patches. These tools serve surgeons and interventionalists worldwide. The company operates through direct sales teams and distributors, reaching diverse markets. Incorporated in 1983 and rebranded from Vascutech, Inc. in 2001, LeMaitre has maintained a focus on vascular solutions.
Stock Performance
As of the latest session, LMAT closed at 86.79 USD, down 0.7 USD or 0.80%. The 52-week trading range stands between 71.42 USD and 109.58 USD, signaling moderate volatility over the year. The current market capitalization of 1.96 billion USD places it firmly in the mid-cap segment, appealing to investors who seek balance between growth potential and stability. Daily trading volume reached 86,859 shares, below its average of 169,832, which may suggest reduced short-term trading interest.
Market Position and Sector
Operating in the healthcare sector, specifically within the Medical Instruments & Supplies industry, LeMaitre Vascular benefits from ongoing demand for surgical devices and implants. The company competes with other specialized medical device manufacturers, and its niche focus on peripheral vascular disease gives it a targeted market advantage. Long-term industry growth is supported by demographic trends and rising rates of vascular health conditions.
Governance and Leadership
George W. LeMaitre serves as the Chief Executive Officer, guiding the company’s strategy and operational execution. Leadership stability is critical for managing product innovation and maintaining quality standards demanded by healthcare providers. Under his oversight, the company has expanded its product line while managing regulatory compliance across global markets.
Key Financial Data
Investors examining LMAT should note several important financial indicators:
- Price: 86.79 USD — benchmarking current valuation in relation to historical ranges.
- Market Capitalization: 1.96 billion USD — reflecting total equity market value, influencing index eligibility and institutional interest.
- Dividend: 0.76 USD — indicating shareholder return policy via cash distribution.
- 52-week range: 71.42–109.58 USD — providing a snapshot of volatility and potential resistance/support levels.
- Volume: 86,859 shares — compared to average volume of 169,832 shares, showing current turnover.
Trading details add further clarity for financial professionals: LMAT trades on the NASDAQ Global Market, has ISIN US5255582018, and CUSIP 525558201. Its CIK number is 0001158895, essential for SEC filings. The company IPO’d on October 19, 2006, marking nearly two decades of public market presence.
FAQ
- Does LeMaitre Vascular pay dividends? Yes, currently 0.76 USD per share annually.
- How many employees does the company have? 651 full-time employees.
- What exchange does LMAT trade on? NASDAQ Global Market.
- Is LMAT actively trading today? Yes, it is listed as actively trading.
- What is the CUSIP number? 525558201.
Conclusion
LeMaitre Vascular stands as a stable player in its industry despite recent minor stock declines. The mid-cap valuation, regular dividend, and consistent niche market strategy provide a balanced investment profile. Further shifts in volume and price range will be key signals for traders in the coming months.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence or consult professional advisors before making investment decisions.
Official Source
For full information about the company, see the link below.
https://www.lemaitre.com